The professional acne treatment market will grow at a compound annual growth rate of 7.6% by the end of this decade to reach a value of USD 13,124.5 million by 2030. 

This growth of the industry has a lot to do with the increasing occurrence of acne, rising disposable income in developing and developed countries, growing healthcare outlay, and growing count of research programs.

Inflammatory acne was the larger category in the past in the industry, on the basis of acne type. This has a lot to do with the instant need for effective treatment since it is usually painful. 

Also, the commonly obtainable salicylic acid and benzoyl-peroxide-based OTC products are not completely effective on inflammatory acne. So, generic and branded drugs are provided by major pharma companies on prescription for inflammatory acne.

The devices category will grow at a faster rate in the industry in the years to come, on the basis of treatment type. This will chiefly be as a result of the increasing acceptance of laser- and light-based acne treatments, mostly in advanced economies, as a result of the drug side-effects.

Download free sample pages of this report: https://www.psmarketresearch.com/market-analysis/professional-acne-treatment-market/report-sample

The dermatologists will lead the professional acne treatment market in the future, on the basis of professional type. This is credited to the snowballing count of skilled dermatologists treating skin ailments, such as acne. 

Moreover, patients choose dermatologists for the reason of their extensive know-how and experience in coping with the issues.

North America was the leader of the industry thanks to the increasing occurrence of acne, growing consciousness on newly advanced drugs, large drug pipeline, and high income per capita. 

Furthermore, the region is marked by the existence of protruding dermatology drug manufacturers, like Bausch Health Companies Inc., Johnson & Johnson, and Pfizer Inc., providing many classes of drugs to the regional population.

Many pharma companies are introducing new products, becoming a key trend in the industry. For example, in August 2020, Cassiopea SpA received the FDA approval for Winlevi, a cream designed for treating acne in patients of twelve years and older. 

Furthermore, AnnJi Pharmaceutical Co. Ltd. engaged in the expansion of AJ101, a topical cream for treating acne vulgaris. The active element in AJ101 is a new androgen receptor degradation enhancer, effectively reduces activity level of the androgen receptor, arbitrated by the ubiquitin–proteasome system with the help of activation of the Nrf1 pathway.

Acne is perhaps the most common skin issue all over the world. And, because of the increasing number of acne treatments happening, it will have a positive impact on the demand for professional acne treatment in the years to come.